|
1
|
Ostrom QT, Gittleman H, Liao P, Rouse C,
Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2007-2011. Neuro Oncol.
16(Suppl 4): iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Salcman M: Glioblastoma multiforme. Am J
Med Sci. 279:84–94. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005-2009.
Neuro Oncol. 14(Suppl 5): v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ala A, Walker AP, Ashkan K, Dooley JS and
Schilsky ML: Wilson's disease. Lancet. 369:397–408. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kahlson MA and Dixon SJ: Copper-induced
cell death. Science. 375:1231–1232. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grasso M, Bond GJ, Kim YJ, Boyd S, Matson
Dzebo M, Valenzuela S, Tsang T, Schibrowsky NA, Alwan KB, Blackburn
NJ, et al: The copper chaperone CCS facilitates copper binding to
MEK1/2 to promote kinase activation. J Biol Chem. 297:1013142021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia W, Tian H, Jiang J, Zhou L, Li L, Luo
M, Ding N, Nice EC, Huang C and Zhang H: Brain-targeted HFn-Cu-REGO
nanoplatform for site-specific delivery and manipulation of
autophagy and cuproptosis in glioblastoma. Small. 19:e22053542023.
View Article : Google Scholar
|
|
8
|
Tsvetkov P, Detappe A, Cai K, Keys HR,
Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, et al:
Mitochondrial metabolism promotes adaptation to proteotoxic stress.
Nat Chem Biol. 15:681–689. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang L, Zhang Y, Wang Y, Jiang P, Liu F
and Feng N: Ferredoxin 1 is a cuproptosis-key gene responsible for
tumor immunity and drug sensitivity: A pan-cancer analysis. Front
Pharmacol. 13:9381342022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brem S, Grossman SA, Carson KA, New P,
Phuphanich S, Alavi JB, Mikkelsen T and Fisher JD; New Approaches
to Brain Tumor Therapy CNS Consortium: Phase 2 trial of copper
depletion and penicillamine as antiangiogenesis therapy of
glioblastoma. Neuro Oncol. 7:246–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Hu J, Guan F, Song L, Fan R, Zhu H,
Hu X, Shen E and Yang B: Copper induces cellular senescence in
human glioblastoma multiforme cells through downregulation of
Bmi-1. Oncol Rep. 29:1805–1810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lun X, Wells JC, Grinshtein N, King JC,
Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, et al:
Disulfiram when combined with copper enhances the therapeutic
effects of temozolomide for the treatment of glioblastoma. Clin
Cancer Res. 22:3860–3875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Ma Z and Mei L: Cuproptosis-related
gene SLC31A1 is a potential predictor for diagnosis, prognosis and
therapeutic response of breast cancer. Am J Cancer Res.
12:3561–3580. 2022.PubMed/NCBI
|
|
14
|
Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X and
Song Z: Cuproptosis-related risk score predicts prognosis and
characterizes the tumor microenvironment in hepatocellular
carcinoma. Front Immunol. 13:9256182022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bladt F, Faden B, Friese-Hamim M, Knuehl
C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling
F, et al: EMD 1214063 and EMD 1204831 constitute a new class of
potent and highly selective c-Met inhibitors. Clin Cancer Res.
19:2941–2951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jessa S, Mohammadnia A, Harutyunyan AS,
Hulswit M, Varadharajan S, Lakkis H, Kabir N, Bashardanesh Z,
Hébert S, Faury D, et al: K27M in canonical and noncanonical H3
variants occurs in distinct oligodendroglial cell lineages in brain
midline gliomas. Nat Genet. 54:1865–1880. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arnone AA, Tsai YT, Cline JM, Wilson AS,
Westwood B, Seger ME, Chiba A, Howard-McNatt M, Levine EA, Thomas
A, et al: Endocrine-targeting therapies shift the breast microbiome
to reduce estrogen receptor-α breast cancer risk. Cell Rep Med.
6:1018802025. View Article : Google Scholar
|
|
18
|
Wu Z, Li W, Zhu H, Li X, Zhou Y, Chen Q,
Huang H, Zhang W, Jiang X and Ren C: Identification of
cuproptosis-related subtypes and the development of a prognostic
model in glioma. Front Genet. 14:11244392023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishiyama A and Nakanishi M: Navigating
the DNA methylation landscape of cancer. Trends Genet.
37:1012–1027. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang H and Bu L: Progress in the
treatment of lung adenocarcinoma by integrated traditional Chinese
and Western medicine. Front Med (Lausanne). 10:13233442024.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L, Xu YX, Wang YS, Ren YY, Chen YM,
Zheng C, Xie T, Jia YJ and Zhou JL: Integrative Chinese-Western
medicine strategy to overcome docetaxel resistance in prostate
cancer. J Ethnopharmacol. 331:1182652024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin J, Sun L, Chen H, Chen W, Zhang Z, Cao
Y and Lin L: Chinese and Western integrative medicine for stage
IIIb-IVb non-small cell lung cancer: Design and rationale of a
multi-center, prospective registry (NSCLC-Chinese and Western
integrative medicine cohort). Integr Cancer Ther.
22:153473542311851092023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Komori T: The 2016 WHO classification of
tumours of the central nervous system: The major points of
revision. Neurol Med Chir (Tokyo). 57:301–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu W, Klockow JL, Zhang M, Lafortune F,
Chang E, Jin L, Wu Y and Daldrup-Link HE: Glioblastoma multiforme
(GBM): An overview of current therapies and mechanisms of
resistance. Pharmacol Res. 171:1057802021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen L, Min J and Wang F: Copper
homeostasis and cuproptosis in health and disease. Signal Transduct
Target Ther. 7:3782022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koch M, Schulze J, Hansen U, Ashwodt T,
Keene DR, Brunken WJ, Burgeson RE, Bruckner P and Bruckner-Tuderman
L: A novel marker of tissue junctions, collagen XXII. J Biol Chem.
279:22514–22521. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang ML and Luo WL: Engrailed homeobox 1
transcriptional regulation of COL22A1 inhibits nasopharyngeal
carcinoma cell senescence through the G1/S phase arrest. J Cell Mol
Med. 26:5473–5485. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Misawa K, Kanazawa T, Imai A, Endo S,
Mochizuki D, Fukushima H, Misawa Y and Mineta H: Prognostic value
of type XXII and XXIV collagen mRNA expression in head and neck
cancer patients. Mol Clin Oncol. 2:285–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan R, Pan F, Zeng Z, Lei S, Yang Y, Yang
Y, Hu C, Chen H and Tian X: A novel immune cell signature for
predicting osteosarcoma prognosis and guiding therapy. Front
Immunol. 13:10171202022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu
J, Yu X and Shi S: Applications of single-cell sequencing in cancer
research: Progress and perspectives. J Hematol Oncol. 14:912021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Papalexi E and Satija R: Single-cell RNA
sequencing to explore immune cell heterogeneity. Nat Rev Immunol.
18:35–45. 2018. View Article : Google Scholar
|
|
32
|
Ofengeim D, Giagtzoglou N, Huh D, Zou C
and Yuan J: Single-Cell RNA sequencing: Unraveling the brain one
cell at a time. Trends Mol Med. 23:563–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Walker K and Padhiar M:
AACR-NCI-EORTC--21st international symposium. Molecular targets and
cancer therapeutics-Part 2. IDrugs. 13:10–12. 2010.
|
|
34
|
Devi KP, Malar DS, Nabavi SF, Sureda A,
Xiao J, Nabavi SM and Daglia M: Kaempferol and inflammation: From
chemistry to medicine. Pharmacol Res. 99:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang RY, Lin S and Kuo G: Content and
distribution of flavonoids among 91 edible plant species. Asia Pac
J Clin Nutr. 17(Suppl 1): S275–S279. 2008.
|
|
36
|
Calderón-Montaño JM, Burgos-Morón E,
Pérez-Guerrero C and López-Lázaro M: A review on the dietary
flavonoid kaempferol. Mini Rev Med Chem. 11:298–344. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim TW, Lee SY, Kim M, Cheon C and Ko SG:
Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway
and inhibition of G9a in gastric cancer cells. Cell Death Dis.
9:8752018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Yang Y, An Y and Fang G: The
mechanism of anticancer action and potential clinical use of
kaempferol in the treatment of breast cancer. Biomed Pharmacother.
117:1090862019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tie F, Ding J, Hu N, Dong Q, Chen Z and
Wang H: Kaempferol and kaempferide attenuate oleic acid-induced
lipid accumulation and oxidative stress in HepG2 cells. Int J Mol
Sci. 22:88472021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin CW, Shen SC, Chien CC, Yang LY, Shia
LT and Chen YC: 12-O-tetradecanoylphorbol-13-acetate-induced
invasion/migration of glioblastoma cells through activating
PKCalpha/ERK/NF-kappaB-dependent MMP-9 expression. J Cell Physiol.
225:472–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Imran M, Salehi B, Sharifi-Rad J, Aslam
Gondal T, Saeed F, Imran A, Shahbaz M, Tsouh Fokou PV, Umair Arshad
M, Khan H, et al: Kaempferol: A key emphasis to its anticancer
potential. Molecules. 24:22772019. View Article : Google Scholar : PubMed/NCBI
|
